Lung Cancer

Brigatinib, Next-Generation ALK Inhibitor, Improves Survival versus Crizotinib in Patients with NSCLC and ALK Mutation

Phoebe Starr

January 2019, Vol 9, No 1 - Lung Cancer

Brigatinib (Alunbrig), a new-­generation ALK inhibitor, significantly prolonged survival compared with standard of care with crizotinib (Xalkori) as first-line therapy in patients with advanced ALK-positive non–small-cell lung cancer (NSCLC). The median progression-free survival (PFS) was not reached in the brigatinib arm versus 9.8 months in the crizotinib arm. At 1 year, 67% of the patients who received brigatinib were still alive compared with 43% of patients who received crizotinib. [ Read More ]

New First-Line Regimen for Small-Cell Lung Cancer: Atezolizumab plus Chemotherapy

Phoebe Starr

November 2018, Vol 8, No 11 - Lung Cancer

Although many new treatments, including targeted therapies and immunotherapies, have recently become available for patients with non–small-cell lung cancer, those with small-cell lung cancer have not seen new treatment options in the past 2 decades. But this is about to change. (In August 2018, the FDA approved the immunotherapy nivolumab (Opdivo) for patients with metastatic small-cell lung cancer.) [ Read More ]

NCCN Drug Affordability Ratings Miss the Mark in Lung Cancer

Wayne Kuznar

November 2018, Vol 8, No 11 - Lung Cancer, Value-Based Care

The drug affordability rating in the National Comprehensive Cancer Network (NCCN) Evidence Blocks are inconsistent with real-world total episode of care costs, according to Scott D. Ramsey, MD, PhD, Director, Institute for Cancer Outcomes Research, Fred Hutchinson Cancer Research Center, Seattle, WA. He presented the results of a recent analysis at ASCO 2018. [ Read More ]

A Home Run for Pembrolizumab plus Chemotherapy Combination in Newly Diagnosed Metastatic Non–Small-Cell Lung Cancer

Phoebe Starr

June 2018, Vol 8, No 6 - Lung Cancer

A burning question is whether immunotherapy combinations will further improve outcomes compared with checkpoint inhibitor therapy alone—and if so, which combinations will rise to the top. Combining pembrolizumab (Key­truda) with standard pemetrexed (Alimta) plus a platinum-based chemotherapy improved overall survival (OS) versus chemotherapy alone as first-line therapy for patients with metastatic nonsquamous non–small-cell lung cancer (NSCLC) in KEYNOTE-189, a phase 3 clinical trial. The survival benefit with pembroliz­umab plus chemotherapy was independent of PD-L1 expression. [ Read More ]

High Tumor Mutational Burden Predicts Response to Nivolumab plus Ipilimumab Combination in Lung Cancer

Phoebe Starr

June 2018, Vol 8, No 6 - Lung Cancer

The combination of nivolumab (Opdivo) plus ipilimumab (Yervoy) extended progression-free survival (PFS) versus standard chemotherapy as first-line treatment for patients with advanced non–small-cell lung cancer (NSCLC) and a high tumor mutational burden (TMB). This finding was unrelated to levels of PD-L1 expression, said Matthew D. Hellmann, MD, Medical Oncologist, Memorial Sloan Kettering Cancer Center, New York City. [ Read More ]

Alunbrig (Brigatinib) Approved for Metastatic NSCLC with ALK Mutation

Lisa A. Raedler, PhD, RPh

2018 Third Annual Oncology Guide to New FDA Approvals - FDA Approvals, News & Updates, Lung Cancer

Lung cancer is one of the most common cancers in men and women, and is the leading cause of cancer-related mortality in the United States. According to the American Cancer Society, more than 155,000 Americans will die from lung cancer in 2017, representing approximately 25% of all cancer deaths. Non–small-cell lung cancer (NSCLC), the most common form of the disease, accounts for 80% to 85% of all lung cancer cases. [ Read More ]